BNET Industries
Chelsea Therapeutics International Ltd. (CHTP) is in the Pharma Industry
- Profit
- Dec 31 2007
- ($15.0M)
- Market Cap
- Jul 23 2008
- $192.8M
Latest News and Analysis
Chelsea Therapeutics Int. Q4 2007 Earnings Call Transcript
Chelsea Therapeutics Int. Q4 2007 Earnings Call Transcript
Additional Resources
AGT, SGN, AGIX, CHTP, SOLM, BZLFY Have Been Removed From Naked Short List Today.
M2 PRESSWIRE-1 April 2008-BUYINS.NET: AGT, SGN, AGIX, CHTP, SOLM, BZLFY Have Been Removed From Naked Short List TodayC1994-2008 M2 COMMUNICATIONS LTD RDATE:01042008 BUYINS.NET, www.buyins.net, announced today that these select companies have been removed from the NASDAQ, AMEX and NYSE...
NRF, WAL, CHTP, EFSC, GTOP, MCEL Have Been Added To Naked Short List Today.
M2 PRESSWIRE-1 April 2008-BUYINS.NET: NRF, WAL, CHTP, EFSC, GTOP, MCEL Have Been Added To Naked Short List TodayC1994-2008 M2 COMMUNICATIONS LTD RDATE:01042008 BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE...
NRF, WAL, CEGE, CHTP, EFSC, GTOP Have Been Added To Naked Short List Today.
M2 PRESSWIRE-24 March 2008-BUYINS.NET: NRF, WAL, CEGE, CHTP, EFSC, GTOP Have Been Added To Naked Short List TodayC1994-2008 M2 COMMUNICATIONS LTD RDATE:24032008 BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE...
CHELSEA THERAPEUTICS INITIATES PHASE II TRIAL OF CH-1504.(Medical condition overview)
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), Charlotte, N.C., has initiated enrollment and patient dosing in a multinational, 12-week, double-blind Phase II trial designed to compare the efficacy and tolerability of CH-1504 against methotrexate MTX in rheumatoid arthritis RA patients. CH-1504, a non-metabolized antifolate,...
Chelsea Therapeutics Initiates Ch-150 Bioequivalence Study
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), Charlotte, N.C., has begun dosing volunteers in its bioequivalence study of CH-1504, an orally available metabolically inert antifolate which has demonstrated potential anti-inflammatory and anti-tumor properties. The bioequivalence study, being conducted at Swiss Pharma in Basel, Switzerland, is intended to determine a comparable...
ATB, HOV, VG, CEGE, CHTP, CNTF Have Been Removed From Naked Short List Today.
M2 PRESSWIRE-16 July 2007-BUYINS.NET: ATB, HOV, VG, CEGE, CHTP, CNTF Have Been Removed From Naked Short List TodayC1994-2007 M2 COMMUNICATIONS LTD RDATE:16072007 BUYINS.NET, www.buyins.net, announced today that these select companies have been removed from the NASDAQ, AMEX and NYSE naked short...
CDZI, CHTP, CKEC, CONN, CSFL, CUTR Have Also Been Added To Naked Short List Today.
M2 PRESSWIRE-5 July 2007-BUYINS.NET: CDZI, CHTP, CKEC, CONN, CSFL, CUTR Have Also Been Added To Naked Short List TodayC1994-2007 M2 COMMUNICATIONS LTD RDATE:05072007 BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE naked...
Chelsea Therapeutics to Raise $12.5 Million Through Equity Financing.
M2 PRESSWIRE-19 March 2007-Catalyst Reporting: Chelsea Therapeutics to Raise $12.5 Million Through Equity FinancingC1994-2007 M2 COMMUNICATIONS LTD RDATE:19032007 Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead of the ...
Active Biotech's I-3D micro-dosing clinical trial concluded
Active Biotech AB (Stockholm:ACTI.ST)and Chelsea TherapeuticsInternational Ltd (NASDAQ: CHTP) has performed a first humanmicro-dosing trial of an I-3D compound. The aim of the study was to determine thepharmacokineticcharacteristics of the compound in humans. The trial was performedinhealthy volunteers. The study...
FDA GRANTS ORPHAN DRUG DESIGNATION FOR DROXIDOPA.
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), Charlotte, N.C., has announced that the U.S. Food and Drug Administration FDA has granted Orphan Drug designation to its drug candidate Droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension NOH in patients with Primary Autonomic Failure, a group of diseases...
Market Commentary on Chelsea Therapeutics International Ltd.
M2 PRESSWIRE-1 February 2007-Biotech News: Market Commentary on Chelsea Therapeutics International LtdC1994-2007 M2 COMMUNICATIONS LTD RDATE:01022007 Market Commentary on Chelsea Therapeutics International Ltd (NASDAQ:CHTP) Chelsea Therapeutics International, Ltd. engages in the acquisition, development, and commercialization of pharmaceutical ...
Droxidopa granted Orphan Drug designation.(Industry News)
Chelsea Therapeutics International, Ltd. has announced that the FDA has granted Orphan Drug designation to its drug candidate Droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension NOH in patients with Primary Autonomic Failure, a group of diseases that includes Parkinson's Disease, Pure Autonomic Failure PAF...
Trade Alert for Chelsea Therapeutics International Ltd.
M2 PRESSWIRE-1 February 2007-Biotech News: Trade Alert for Chelsea Therapeutics International LtdC1994-2007 M2 COMMUNICATIONS LTD RDATE:01022007 Trade Alert for Chelsea Therapeutics International Ltd (NASDAQ:CHTP) Chelsea Therapeutics International, Ltd. engages in the acquisition, development, and commercialization of pharmaceutical ...
Global Market Perspective Review on Chelsea Therapeutics International Ltd.
M2 PRESSWIRE-23 January 2007-www.streetinvesting.com: Global Market Perspective Review on Chelsea Therapeutics International Ltd.C1994-2007 M2 COMMUNICATIONS LTD RDATE:23012006 Please visit www.Streetinvesting.com for the full report. Although Wall Street exhibited an overall decline Monday, investors of Chelsea Therapeutics International Ltd....
Alerts for Monday, September 11, 2006 - Featuring Conforce International, Critical Path, Manakoa Services, Chelsea Therapeutics International and More.
M2 PRESSWIRE-11 September 2006-Stockguru.com: Alerts for Monday, September 11, 2006 - Featuring Conforce International, Critical Path, Manakoa Services, Chelsea Therapeutics International and MoreC1994-2006 M2 COMMUNICATIONS LTD RDATE:11092006 Dallas, Texas - StockGuru Pre-Market Updates for Monday include Conforce International, Inc. (OTC:...
Price and Volume Alerts for Thursday, September 7, 2006 - Featuring PURE Bioscience , Earth Biofuels,,NanoSensors, Lifeline Biotechnologies, and More.
M2 PRESSWIRE-7 September 2006-Stockguru.com: Price and Volume Alerts for Thursday, September 7, 2006 - Featuring PURE Bioscience , Earth Biofuels,,NanoSensors, Lifeline Biotechnologies, and MoreC1994-2006 M2 COMMUNICATIONS LTD RDATE:07092006 Dallas, Texas - StockGuru Pre-Market Updates for Thursday include PURE Bioscience (OTCBB:...
Morning Updates for Wednesday, September 6, 2006 - Featuring: Patriot Motorcycle, Signature Leisure, NaturalNano, Inyx, and More.
M2 PRESSWIRE-6 September 2006-Stockguru.com: Morning Updates for Wednesday, September 6, 2006 - Featuring: Patriot Motorcycle, Signature Leisure, NaturalNano, Inyx, and More.C1994-2006 M2 COMMUNICATIONS LTD RDATE:06092006 Dallas, Texas - StockGuru Pre-Market Updates for Wednesday include Patriot Motorcycle Corporation (OTC: PMCY), Signature Leisure,...
Price and Volume Alerts for Thursday, August 31, 2006 - Featuring Chelsea Therapeutics International,PhytoMedical Technologies, Startech Environmental, EarthFirst Technologies and More.
M2 PRESSWIRE-31 August 2006-Stockguru.com: Price and Volume Alerts for Thursday, August 31, 2006 - Featuring Chelsea Therapeutics International,PhytoMedical Technologies, Startech Environmental, EarthFirst Technologies and MoreC1994-2006 M2 COMMUNICATIONS LTD RDATE:31082006 Dallas, Texas - StockGuru Pre-Market Updates for Thursday include Chelsea Therapeutics...
Price and Volume Alerts for Thursday August 24, 2006 - Featuring ATSI Communications, China Digital Media, Colombia Goldfields, Chelsea Therapeutics International,and More.
M2 PRESSWIRE-24 August 2006-Stockguru.com: Price and Volume Alerts for Thursday August 24, 2006 - Featuring ATSI Communications, China Digital Media, Colombia Goldfields, Chelsea Therapeutics International,and MoreC1994-2006 M2 COMMUNICATIONS LTD RDATE:24082006 Dallas, Texas - StockGuru Price and Volume Alerts for Thursday ...
- Next »
- page 1 of 3
- « Previous
Sort byClose
- Incorporated: 2002
- CEO: Dr. Simon Pedder Ph.D.
Chelsea Therapeutics International is a development stage pharmaceutical company. Co. is developing two platform technologies that each consist of a portfolio of molecules for the treatment of various autoimmune/inflammatory diseases. These platforms include Co.'s key product candidate, CH-1504, an orally molecule with potent anti-inflammatory, autoimmune and anti-tumor properties and I-3D portfolio that is being co-developed with Active Biotech AB. Co. is also developing droxidopa, an orally active synthetic precursor of norepinephrine for the treatment of symptomatic orthostatic hypotension, freezing gait in Parkinson's disease, and for intra dialytic hypotension.
Key Competitors
Chelsea Therapeutics International Ltd. Company Info
Board of Directors
Dr. Kevan Clemens Ph.D.
Chairman
Dr. Simon Pedder Ph.D.
Dr. Johnson Y.N. Lau M.D.
Dr. Michael Weiser M.D., Ph
Dr. Roger G. Stoll Ph.D.
Dr. Norman Hardman Ph.D.
Dr. William D. Schwieterman M.D.
Contact Information
13950 Ballantyne Corporate Place, Suite 325
Charlotte, NC
704 341-1516
